RCKT Long Call Strategy

RCKT (Rocket Pharmaceuticals, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; CIEMAT and UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. is headquartered in Cranbury, New Jersey.

RCKT (Rocket Pharmaceuticals, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $393.1M, a beta of 0.52 versus the broader market, a 52-week range of 2.19-7.14, average daily share volume of 3.4M, a public-listing history dating back to 2015, approximately 299 full-time employees. These structural characteristics shape how RCKT stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 0.52 indicates RCKT has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.

What is a long call on RCKT?

A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration.

Current RCKT snapshot

As of May 15, 2026, spot at $3.25, ATM IV 119.40%, IV rank 30.51%, expected move 34.23%. The long call on RCKT below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.

Why this long call structure on RCKT specifically: RCKT IV at 119.40% is mid-range versus its 1-year history, so strategy selection should anchor more to the directional thesis than to the IV regime, with a market-implied 1-standard-deviation move of approximately 34.23% (roughly $1.11 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated RCKT expiries trade a higher absolute premium for lower per-day decay. Position sizing on RCKT should anchor to the underlying notional of $3.25 per share and to the trader's directional view on RCKT stock.

RCKT long call setup

The RCKT long call below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With RCKT near $3.25, the first option leg uses a $3.25 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed RCKT chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 RCKT shares for the stock leg in covered calls and collars).

ActionTypeStrike / BasisPremium (est)
Buy 1Call$3.25N/A

RCKT long call risk and reward

Net Premium / Debit
N/A
Max Profit (per contract)
Unbounded
Max Loss (per contract)
Unbounded
Breakeven(s)
None on modeled curve
Risk / Reward Ratio
N/A

Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium.

RCKT long call payoff curve

Modeled P&L at expiration across a range of underlying prices for the long call on RCKT. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

When traders use long call on RCKT

Long calls on RCKT express a bullish thesis with defined risk; traders use them ahead of RCKT catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.

RCKT thesis for this long call

The market-implied 1-standard-deviation range for RCKT extends from approximately $2.14 on the downside to $4.36 on the upside. A RCKT long call expresses a directional view that the underlying closes above the strike plus premium at expiration, ideally with implied volatility holding or expanding to preserve extrinsic value through the hold period. Current RCKT IV rank near 30.51% is mid-range against its 1-year distribution, so the IV signal is neutral; the long call thesis on RCKT should anchor more to the directional view and the expected-move geometry. As a Healthcare name, RCKT options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to RCKT-specific events.

RCKT long call positions are structurally bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. RCKT positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move RCKT alongside the broader basket even when RCKT-specific fundamentals are unchanged. Long-premium structures like a long call on RCKT are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current RCKT chain quotes before placing a trade.

Frequently asked questions

What is a long call on RCKT?
A long call on RCKT is the long call strategy applied to RCKT (stock). The strategy is structurally bullish: A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration. With RCKT stock trading near $3.25, the strikes shown on this page are snapped to the nearest listed RCKT chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are RCKT long call max profit and max loss calculated?
Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium. For the RCKT long call priced from the end-of-day chain at a 30-day expiry (ATM IV 119.40%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a RCKT long call?
The breakeven for the RCKT long call priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current RCKT market-implied 1-standard-deviation expected move is approximately 34.23%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a long call on RCKT?
Long calls on RCKT express a bullish thesis with defined risk; traders use them ahead of RCKT catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
How does current RCKT implied volatility affect this long call?
RCKT ATM IV is at 119.40% with IV rank near 30.51%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.

Related RCKT analysis